DE60332122D1 - Gentherapie des auges - Google Patents

Gentherapie des auges

Info

Publication number
DE60332122D1
DE60332122D1 DE60332122T DE60332122T DE60332122D1 DE 60332122 D1 DE60332122 D1 DE 60332122D1 DE 60332122 T DE60332122 T DE 60332122T DE 60332122 T DE60332122 T DE 60332122T DE 60332122 D1 DE60332122 D1 DE 60332122D1
Authority
DE
Germany
Prior art keywords
choroidal neovascularization
eye
gene therapy
vivo
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60332122T
Other languages
German (de)
English (en)
Inventor
Peter Anthony Campochiaro
Michael Kaleko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31978303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60332122(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Application granted granted Critical
Publication of DE60332122D1 publication Critical patent/DE60332122D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60332122T 2002-08-28 2003-08-27 Gentherapie des auges Expired - Lifetime DE60332122D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40647002P 2002-08-28 2002-08-28
PCT/EP2003/009497 WO2004020469A2 (en) 2002-08-28 2003-08-27 Ocular gene therapy

Publications (1)

Publication Number Publication Date
DE60332122D1 true DE60332122D1 (de) 2010-05-27

Family

ID=31978303

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60332122T Expired - Lifetime DE60332122D1 (de) 2002-08-28 2003-08-27 Gentherapie des auges

Country Status (11)

Country Link
US (1) US20070104684A1 (enExample)
EP (1) EP1534751B1 (enExample)
JP (1) JP4612417B2 (enExample)
CN (2) CN101637611A (enExample)
AT (1) ATE464321T1 (enExample)
AU (1) AU2003258675B2 (enExample)
CA (1) CA2496820A1 (enExample)
DE (1) DE60332122D1 (enExample)
IL (1) IL166950A (enExample)
NZ (1) NZ538958A (enExample)
WO (1) WO2004020469A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174861B1 (en) 1996-10-22 2001-01-16 The Children's Medical Center Corporation Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein
JP2001517433A (ja) * 1997-09-24 2001-10-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 非霊長類レンチウイルスベクターおよびパッケージングシステム
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
US6670321B1 (en) * 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
EP1280929A2 (en) * 2000-05-01 2003-02-05 Novartis AG Vectors for ocular transduction and use thereof for genetic therapy
WO2001093897A2 (en) * 2000-06-02 2001-12-13 Entremed, Inc. Angiostatin and endostatin binding proteins and methods of use
AU2002224403A1 (en) * 2000-10-13 2002-04-22 Entremed, Inc Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use
EP1401480B1 (en) * 2001-02-22 2012-11-28 Novartis AG Viral vectors encoding endostatin in the treatment of ocular neovascularization
AU2003225544A1 (en) * 2002-02-04 2003-09-02 Novartis Ag Recombinant bovine immunodeficiency virus based gene transfer system
CA2480809A1 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
WO2004028635A1 (en) * 2002-09-27 2004-04-08 Novartis Ag Ocular gene therapy

Also Published As

Publication number Publication date
WO2004020469A2 (en) 2004-03-11
CN101637611A (zh) 2010-02-03
JP2006516112A (ja) 2006-06-22
CN1708513A (zh) 2005-12-14
WO2004020469A3 (en) 2004-04-29
IL166950A (en) 2011-04-28
EP1534751B1 (en) 2010-04-14
CA2496820A1 (en) 2004-03-11
AU2003258675B2 (en) 2009-03-26
AU2003258675A1 (en) 2004-03-19
HK1077306A1 (en) 2006-02-10
EP1534751A2 (en) 2005-06-01
NZ538958A (en) 2006-09-29
US20070104684A1 (en) 2007-05-10
ATE464321T1 (de) 2010-04-15
JP4612417B2 (ja) 2011-01-12
CN100526332C (zh) 2009-08-12

Similar Documents

Publication Publication Date Title
MX2010003774A (es) Formulaciones oftalmicas acuosas.
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
BRPI0516377A (pt) inibição de rnai de ctgf para tratamento de distúrbios oculares
WO2002067971A3 (en) Use of endostatin in the treatment of ocular neovascularization
EA200901211A1 (ru) Антигены белка с5 и их применение
DK2195013T3 (da) Terapeutisk anvendelse af en vækstfaktor, METRNL
TW200502385A (en) Modulation of forkhead box o1a expression
EA201101576A1 (ru) Лекарственная форма токотриенол хинонов для лечения офтальмических (глазных) заболеваний
ES2674129T3 (es) Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento
MY137053A (en) Pyrimidine derivatives and their use as cb2 modulators
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
EP4124346A3 (en) Compositions and methods for treating diseases
WO2021174107A3 (en) Soluble ace2 variants and uses therefor
EP2401648A4 (en) LENS PORT OF ORTHOKERATOLOGY COMBINED WITH CHEMICAL TREATMENT TO CORRECT MYOPIA, HYPERMETROPY OR ASTIGMATIA
WO2008067040A3 (en) Method of detecting ocular diseases and pathologic conditions and treatment of same
TW200611695A (en) Pyrrolopyridine derivatives
EA200970345A1 (ru) Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина
GB0416508D0 (en) Therapeutic agents
MXPA05008561A (es) Uso de esteroides para tratar personas que sufren de trastornos oculares.
WO2004024089A3 (en) Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing
EA200700772A1 (ru) Аналоги полиаминов в качестве терапевтических средств для глазных заболеваний
DE60332122D1 (de) Gentherapie des auges
MX2009005503A (es) Uso de l-carnitina para la preparacion de un medicamento en forma de gotas oculares para el tratamiento de enfermedades de la cornea.

Legal Events

Date Code Title Description
8363 Opposition against the patent